Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-20

Clinical Trial Update: Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of TNX-102 SL in military-related post-traumatic stress disorder has completed and posted results on 2024-06-20.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TNX-102 SL (cyclobenzaprine hydrochloride)

Snippet

Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: PTSD | Phase 2 | Status: COMPLETED | Results posted: 2024-06-20